All the below link and tweets are in English.
取り急ぎ以下貼っておきます。
Indiana Vol.8 (corporations: Eli Lilly)
追加
COVID-19 SETBACKS: As hospitalizations climb in America – with a field hospital set to open in Wisconsin Wednesday – Johnson & Johnson and Eli Lilly are reporting setbacks on vaccine and antibody treatment trials, respectively. @sramosABC reports. https://t.co/GnnUv1Mazk pic.twitter.com/PpPYNsCWBP
— World News Tonight (@ABCWorldNews) October 14, 2020
Eli Lilly says it is pausing the trial of its coronavirus antibody treatment because of a safety concern https://t.co/1H99MmaraN Johnson & Johnson said on Monday it would pause its COVID-19 vaccine trial due to an unexplained illness https://t.co/fTnt6q7uwa pic.twitter.com/EQzoQcBoX0
— Reuters (@Reuters) October 13, 2020
“This is an indication that the system is working as it was designed to work to protect human subjects in clinical trials,” said Lawrence Gostin, a public health and legal expert at Georgetown and Johns Hopkins universities. https://t.co/pZkPkzRSt2
— Statesman Journal (@Salem_Statesman) October 14, 2020
Coronavirus update: Regeneron, Eli Lilly seek FDA approval of antibodies, boosted by Trump's bout with COVID https://t.co/OdhsKigIwu by @AnjKhem pic.twitter.com/m05Ue3NYJi
— Yahoo Finance (@YahooFinance) October 11, 2020
Coronavirus update: Eli Lilly eyes emergency use for antibodies; Trump fumes over FDA vaccine guidelines https://t.co/g84f6tDmOI by @AnjKhem pic.twitter.com/ykVbjTX68x
— Yahoo Finance (@YahooFinance) October 8, 2020
The US pharmaceutical firm Eli Lilly announced it had applied for an emergency use authorization (EUA) for a lab-produced antibody treatment against Covid-19, after early trial results showed it reduced viral load, symptoms and hospitalization rates https://t.co/lOiibBnhLm
— AFP news agency (@AFP) October 7, 2020
ICYMI: @BillGates explains how the Bill & Melinda Gates Foundation has been “working with the companies doing antibodies” research for Covid-19 treatment. #MTP
Gates: “We’re partnered with Eli Lilly, who with Regeneron, has been the fastest to get these antibodies ready.” pic.twitter.com/JjAHoYGZPf
— Meet the Press (@MeetThePress) October 12, 2020
Project warp speed dropped the ball on antibodies. Was a mistake to focus mostly on vaccines and not enough on scaling up antibodies production (beyond what Regeneron and Eli Lilly can do) https://t.co/33zCOgkzMy
— avidresearch (@avidresearch) October 12, 2020
Monoclonal Antibodies for #SARSCoV2 #COVID19
(Regeneron, Eli Lilly, and Prometheus)
Great report by @apoorva_nyc[1] Monoclonal antibodies are artificially synthesized copies of the most effective antibodies produced naturally by patients. https://t.co/cIh0ylmaIo
— Rajeev Chitguppi MDS (@chitguppi) October 13, 2020
Based on what's in the press release, these are impressive data and will surely lead to EUA for antibodies.
Reduction in ER or hospital visits from 5.8% in placebo to 0.9%. This is first demonstrated efficacy on clinical endpoints.https://t.co/HG4aWLS7nI via @statnews
— Walid Gellad, MD MPH (@walidgellad) October 7, 2020
Was it a blessing or a curse for Eli Lilly & Co. that President Donald Trump was treated with coronavirus antibodies made by rival Regeneron? https://t.co/ZS9tEO0lgv
— Bloomberg (@business) October 13, 2020
Eli Lilly has paused its monoclonal antibodies clinical trial after a participant got sick.
"They can produce infusion reactions and may be associated with everything from mild fever or rashes to anaphylactic shock,” @angie_rasmussen told me https://t.co/cXMPK37b0l @newrepublic
— Melody Schreiber (@m_scribe) October 13, 2020
An update on the Eli Lilly pause: researchers found a difference in the "clinical status" between people getting the placebo and the antibodies. We don't yet know what that means. But it's possible hospitalized patients may not benefit from the treatment.https://t.co/77byH7seUF
— Katherine J. Wu, Ph.D. (@KatherineJWu) October 14, 2020
Eli Lilly halts COVID-19 antibody treatment trial over 'safety concern' https://t.co/bbb5EJsIZm via @nypost
President Trump was given an experimental cocktail of manufactured antibodies to help in his bout with the virus and has since called his treatment a “miracle” and “cure”— Muhammad Zafrullah (@mzafrullah) October 13, 2020
A Regeneron spokesman said its manufacturer "expects to begin delivering product in the first quarter of 2021," and that another company pursuing an EUA for monoclonal antibodies is working to meet demand. That company, Eli Lilly, just paused its trial. https://t.co/tPG7mTo5gO
— Michael Wilner (@mawilner) October 13, 2020
Eli Lilly press release* suggests monoclonal antibodies reduce COVID symptoms and hospital visits
*ie data not yet peer reviewed https://t.co/iP0431dweT
— Tim Lahey (@TimLaheyMD) October 7, 2020
Earlier today, I predicted that Trump would be treated with one of the experimental antibody treatments for #COVID19 (either from Regeneron or Eli Lilly). These work by providing “passive immunity,” similar to convalescent plasma, but are manufactured.https://t.co/ZnPrctsgMr
— Dena Grayson, MD, PhD (@DrDenaGrayson) October 2, 2020
IU and Eli Lilly are working together on potential therapies that range from using plasma from infected people to treat those hospitalized to developing drugs with antibodies to fight coronavirus. https://t.co/TxUYjQKJq3
— IndyStar (@indystar) May 6, 2020
ツイッター検索で 上記製薬会社 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
New post (Cytotoxic Drug Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026| Roche, Eli Lilly, Celgene, Sanofi, eisai, Sumitomo Dainippon Pharma – Apsters News) has been published on FUNDSWIFT – https://t.co/4yzfwj7wW4 pic.twitter.com/fEus7AeoVx
— FundSwift (@fundswift) July 8, 2020
Who would want a simple solution?
"thank the leadership of AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Eli Lilly, Evotec, Gilead, GlaxoSmithKline, Johnson & Johnson, KSQ Therapeutics, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vir"https://t.co/V20z6DAu2U
— sandeep chakraborty (@sanchak74) June 12, 2020
Great to see so many pharma companies sharing assets and expertise to support research into COVID-19…Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, J&J, Merck, Novartis, Pfizer, and Sanofi. https://t.co/wtWagRqEV5 pic.twitter.com/6pq6mPl4Cm
— Jennifer Harris (@jnharris1189) March 26, 2020
Sanofi and Eisai Pharma are joining Eli Lilly in a lawsuit to overturn a ruling to end the patent protection of Cialis. Read more to find out the implications for patent claims for other pharmaceutical companies: https://t.co/kojTpbi2cl
— INCUBATE (@incub8coalition) July 17, 2019
Breast Cancer Therapeutics Market Factors That Can Have A Sizable Impact On Industry Growth With Players Like AstraZeneca plc, Eli Lilly and Company, Eisai, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Pfizer https://t.co/fizvl2Uiuq via @openPR
— Dr. Maddys (@Maddys53920205) April 18, 2019
Rectal Cancer – Pipeline Review, H2 2018 Featuring AbbVie, Amgen, Eisai, Eli Lilly, Merck, and more – ResearchAn.. https://t.co/7K2X5TDpLA
— Financial Buzz (@financialbuzz) October 19, 2018
The key industrial players in the anti-migraine drugs sales market include Abbott Laboratories, Inc., Eisai Inc., Eli lilly and Company, Pfizer Inc., Astra Zeneca plc. and Glaxo SmithKline Plc. https://t.co/POypY1bebe
— Amit Rade (@Market_Updates_) February 22, 2018
Other companies in the life sciences #COVID19 consortium are @BDandCo, @Boehringer, @biomerieux, Eisai, @LillyPad, @GileadSciences, @GSK, J&J, @Merck, @merckgroup @Pfizer and @sanofi
— Jim Sheldrake (@jimsheldrake) March 26, 2020
It was great to start day two at Biopharma mission presenting #Stemnovate to leadership in India @AstraZeneca, @GSK, @Sanofi, @Abbott, @Amgen, @NestleSkin, @LillyPad , @Serdiapharma, @Roche, @Oppilotech , @Eisai……looking forward to the next phase of meetings at Ahmedabad. pic.twitter.com/epxYmUC8uB
— Stemnovate Limited (@StemnovateL) September 25, 2019
Next for our #BIO2015 coverage: @Baxalta @PanCAN @BioCentury & ECL Eisai Co on the 5 P's of Successful Stakeholder Engagement.
— Eli Lilly and Company (@LillyPad) June 16, 2015
Latest Research Report on Bipolar Depression Treatment Market| GSK, Pfizer, Janssen Inc., Eli Lilly and Company, Allergan, Novartis, AbbVie, AstraZeneca, Otsuka Pharmaceutical Companies – Dagoretti News – Dagoretti News https://t.co/ohlTIlHYDa
— BipolarDays.com (@BipolarDaysNews) January 20, 2020
#SmallMoleculeCancerDrugs Market Rapid Growth And Development In Pharma & Biotech Industries 2018-2026 By Key Players Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Co, Janssen Research and Development, Novartis AG, Pfizer, SANOFI AVENTIS US https://t.co/iuaAxGjYQC
— Michael Jaikishan (@Michaeljaikish1) July 5, 2019
"Editor’s note: The author did not initially disclose having received payments from Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Lundbeck, Merck, Sharpe, and Dohme, Otsuka, Pfizer, and other companies." You have to ask – why the delay? @AmerGeriatrics https://t.co/RWpZYRJ7zK
— James Richardson, MD, MPH (@DocRock54) March 10, 2018
.@TheDDFund $350M raise included $60M from @AARP as part of its #DisruptDementia initiative; fund spearheaded by #biopharma group that included @biogen @LillyPad @GSK @JNJNews Otsuka @pfizer @TakedaPharma
— BioWorld (@BioWorld) June 25, 2018
Otsuka inks deal for rights to migraine drug candidate fremanezumab https://t.co/AcRfmaGiro #biotech @LillyPad
— The Pharma Letter (@ThePharmaLetter) May 17, 2017
Interesting, head of #BorisJohnson's #COVID19 '#Vaccine Task Force', Kate Bingham, on board of DDF Investment Committee – created by 6 leading Pharma giants #GSK, Biogen, Johnson & Johnson, Eli Lilly, Pfizer, Takeda. https://t.co/ZOZ6Re3rxK
— Patrick Henningsen (@21WIRE) September 24, 2020
Biogen, Eli Lilly, Takeda ask staff to work from home to limit coronavirus spread https://t.co/IylUkp7Qse $BIIB $LLY
— FirstWord Pharma (@fwpharma) March 9, 2020
As Biogen grapples with coronavirus crisis, Big Pharmas like Eli Lilly, Takeda hunker down, tell staffers to work from home https://t.co/imJyrr1EQ3
— Endpoints News (@endpts) March 9, 2020
this is new
As Biogen grapples with coronavirus crisis, Big Pharmas like Eli Lilly, Takeda hunker down, tell staffers to work from homehttps://t.co/t6nrWWkjEJ— John Carroll (@JohnCendpts) March 9, 2020
Fujifilm's flu drug Avigan improves COVID-19 recovery time, setting up filing in Japan | @WHO @FujifilmUS @drreddys @ResponseAid @GileadScience @Lillypad @Roche #Covid19 #pneumonia #Biotech #Valhalla #NewYork #Indianapolis #FosterCity #California #Biotech https://t.co/XfSqvA4Xp2
— Aspen Biosciences (@aspenbio) September 24, 2020
The key players in Non-Small Cell Lung Cancer #market include @Novartis, @Merck, @LillyPad, Hoffmann-La-@Roche, @Xcovery, @beyondspring26, @OSEIMMUNO, @sanofi, @Takeda, @abbvie and others.
For more detailed information visit: https://t.co/RWk90xqKhl#LungCancer #Cancer
— DelveInsight (@delve_insight) May 12, 2020
Congratulations again to all finalists in the 2019 @PharmaAwardsIRL and well done to all those in our sponsored category Astellas @bmsnews @LillyPad and @MSDInvents. Looking forward to October 24th.@IrishTimes https://t.co/ijZAo6krPM
— BioPharma Engineering (@BioPharmaE) September 16, 2019
#DRG epidemiology report estimates over 1.5 million people living with #ankylosingspondylitis across the United States, Western Europe and Japan. Check out our detailed global reports for more updates @DRGinsights #spondylitis #FDAapproval @US_FDA @LillyPad https://t.co/0CjXXNZN4T
— DRG Epidemiology (@DRG_Epi) August 27, 2019
#Pharma with '#AI friendly' executives will prosper: US, Germany, and Japan-based companies lead the pack, says @DK_Analytics report // @DeepTech_VC
Read: https://t.co/Ra1FDwHAXE@Boehringer @GSK @LillyPad @Evotec @pfizer @Amgen @BayerPharma @Roche @Novartis @bmsnews @Merck pic.twitter.com/df32pzpwpr
— Outsourcing-Pharma (@OutsourcPharma) July 8, 2019
Eli Lilly (@LillyPad) has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, undercutting a key insulin from Sanofi in the US, but facing safety concerns over a new breast cancer drug in Japan https://t.co/FEpzrbD2aM
— pharmaphorum (@pharmaphorum) May 22, 2019
#DiabetesCellTherapy
Scientists from US and Japan have devised a #newTissueEngineering method to tackle #vascularity problem of transplanted cells
Companies like @LillyPad @Sigilon_Inc are involved in Diabetes cell therapy development
For details click https://t.co/oJMBgdLQ2l— Roots Analysis (@RootsAnalysis) May 9, 2018
@LillyPad keeps #Alimta patent in Japan for now, new challenges on the way$LLYhttps://t.co/bplSR75D4o
— Pharmacutical Daily (@PharmacDaily) February 2, 2017
The #ChicagoOsaka Women’s Leadership Forum featured our CEO Andy Zopp, @1871Chicago CEO @BetsyZEO, Mie Kitano of @LillyPad Japan, President Sachiko Morita of Terrace, and @UnivKansai faculty Masumi Shiraish to discuss global gender equality and #womenleaders in business. pic.twitter.com/tbYDfed5MT
— WorldBusinessChicago (@WorldBizChicago) October 24, 2018
Last week, we helped commemorate @LillyPad’s new office in Kobe, Japan. The company has been headquartered in Indianapolis for more than 140 years. #INJapan pic.twitter.com/Ik6MeY96az
— Indiana in Japan (@InvestIN_Japan) July 17, 2018
Indiana is home to 280+ Japanese businesses & Hoosier firms like @LillyPad, @Cummins, @CookMedical, @zimmerbiomet have facilities in Japan. pic.twitter.com/5RkAw6fv24
— Indiana Economic Development Corp. (@Indiana_EDC) September 12, 2017
#EDGEX2018 Speaker Fun Fact: Newt Crenshaw served as the president of @LillyPad in Japan, where he and his wife also helped establish a new @YoungLife ministry. Join us on October 5 as Newt shares his #leadership journey with us! https://t.co/nSglOE045U pic.twitter.com/r8EBLtRKv4
— EDGE Mentoring (@EDGEMentoring) June 13, 2018
@LillyPad #Drug Receives #Approval in #Japanhttps://t.co/X7VKcQ3DEi pic.twitter.com/w4Mgo6jIKK
— IMA (@IMA1901) July 7, 2017
#TPP "Allied for Innovation" Experts discuss US/Japan common #IP values @globalIPcenter @ITIFdc @USCC_Asia @LillyPad pic.twitter.com/V0yb52OMcW
— Patrick Kilbride (@pjkilbride) April 24, 2015
The U.S., Japan and China were standout markets in Q2 2016. Find out more: https://t.co/4KIV3ZB3nm $LLY pic.twitter.com/d1GMjXxAcQ
— Eli Lilly and Company (@LillyPad) July 27, 2016
Drivers of our Q1 #earnings results include the United States and Japan. Learn more: https://t.co/N0eQxNMDXJ $LLY pic.twitter.com/MRA9JrIGtV
— Eli Lilly and Company (@LillyPad) April 27, 2016
We celebrated Lilly #Japan Day by getting down to the art of the matter. https://t.co/oZFXQWVgrg pic.twitter.com/A54opqm4qq
— Eli Lilly and Company (@LillyPad) December 1, 2015
Speakers shared Lilly #Japan's importance on our 2nd-largest affiliate's 40th anniversary. https://t.co/Ix2v1clkrP pic.twitter.com/23lN8dkp3H
— Eli Lilly and Company (@LillyPad) November 29, 2015
Our #Japan affiliate just marked its 40th anniversary. We held Lilly Japan Day in its honor! https://t.co/Ix2v1clkrP pic.twitter.com/l1SMDRnvWI
— Eli Lilly and Company (@LillyPad) November 25, 2015
Performers took center stage as we celebrated our #Japan affiliate's 40th anniversary! https://t.co/Ix2v1clkrP pic.twitter.com/M61jKy49jf
— Eli Lilly and Company (@LillyPad) November 27, 2015
We're glad to share growth in the U.S. and Japan in Q3. https://t.co/aAFVq1fpjY #earnings $LLY pic.twitter.com/HqKjUjRSdQ
— Eli Lilly and Company (@LillyPad) October 22, 2015
https://twitter.com/LillyPad/status/459766514456215552
https://twitter.com/LillyPad/status/458323201479946240
https://twitter.com/Roxann_Minerals/status/975914779859701762
$LLY Here are the Accord Healthcare/Daiichi Sankyo/Eli Lilly IPR final determination docs. https://t.co/bckhh1Qaw8 https://t.co/iCIt9roKAz
— TradeHawk (@TradeHawk) September 12, 2016
Global Cardiovascular Therapeutics Market 2020-2024 | Evolving Opportunities with Astellas Pharma, Inc. and Eli Lilly and Co. | Technavio https://t.co/w46yHRXwvw pic.twitter.com/z9bYWSGkzP
— Latest News from Business Wire (@NewsFromBW) April 10, 2020
Ependymoma Market Future Innovation Strategies by 2029 | Eli Lilly, Astellas and DNAtrixhttps://t.co/kXAemzI6Mt#news #pharma #pharmiweb
— Pharma News (@pharminews) March 30, 2020
Cancer Treatment Drugs Market Size, Growth, Share and Top Players to 2026: Amgen, Roche, Novartis, Johnson & Johnson, Pfizer, Eli Lilly, Astellas https://t.co/9tASuYljgR pic.twitter.com/CxDF4MHAOF
— PressRelease.cc (@PressRelease_cc) October 1, 2019
Astellas, Eli Lilly must face lawsuit alleging underpaid Medicaid rebates https://t.co/VPhVGWIRf9 @nateraymond ($) pic.twitter.com/1HovatBRq7
— Reuters Legal (@ReutersLegal) April 5, 2019
Antibiotics Market Future Outlook to 2025 – GSK, Sanofi, Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Astellas Pharma, Pfizer, Janssen Inc. and Abbott https://t.co/gErVJuGW0d via @openPR
— Mohammed Alsogaih (@MAlsogaih) September 1, 2018
Eli Lilly, Astellas, China’s ShangPharma and Simcere helped raise $171M for Partners HealthCare System's life science fund. https://t.co/5wJ6YPKUJj
— FierceBiotech (@FierceBiotech) November 9, 2017
Great news! Sekisui has been named in the 2018 Global 100 World’s Most Sustainable Corporations: https://t.co/IQZWtjm4cy Congratulations to UCB, Merck, Allergan, Sanofi, AstraZeneca, Eli Lilly, Takeda, GSK, Novartis, J&J and others who also placed! pic.twitter.com/y6cmX0BRiX
— Sekisui XenoTech (@XenoTechllc) January 26, 2018
Breaking: Jury hits Eli Lilly, Takeda with $9 billion penalty. http://t.co/EIqfJ7JDRl
— IndyStar (@indystar) April 8, 2014
